Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Batiraxcept - Aravive

Drug Profile

Batiraxcept - Aravive

Alternative Names: 3D-229; 3D-299; Aravive-S6; AVB 500; AVB S6 500; Axl fc fusion protein AVB-S6-500; Ruga-S6; S6-500c

Latest Information Update: 09 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stanford University
  • Developer 3D Medicines; Aravive; Aravive Biologics; European Network of Gynaecological Oncological Trial Groups; Gynecologic Oncology Group
  • Class Antifibrotics; Antineoplastics; Antivirals; Immunoglobulin Fc fragments; Immunotherapies; Proteins; Recombinant fusion proteins
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ovarian cancer
  • Phase II IgA nephropathy; Renal fibrosis; Urogenital cancer
  • Phase I/II Fallopian tube cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma
  • Phase I Unspecified
  • Preclinical Cholangiocarcinoma
  • No development reported Acute myeloid leukaemia; Solid tumours
  • Discontinued Viral infections

Most Recent Events

  • 09 Nov 2023 Aravive terminates the phase III AXLerate-OC PROC trial in Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater) in the USA, Belgium, Canada, China, Czech republic, France, Georgia, Greece, Italy, Poland, Spain, United Kingdom, Germany (IV) due to no significant differences observed in median PFS (NCT04729608) (EudraCT2021-000293-28)
  • 26 Oct 2023 Aravive terminates a phase I/II trial in Renal cell carcinoma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) due to business reasons (NCT04300140)
  • 14 Aug 2023 Aravive terminates a phase-I/II trial in Pancreatic cancer (Combination therapy, First-line therapy, Metastatic disease) in USA (IV) due to business reasons(NCT04983407)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top